Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The highest rate (equal or higher than 50%) of those off-label prescriptions in children under five years of age corresponded to simethicone solution (89%), followed by domperidone suspension (69%) and calcium + vitamin D chewable tablets (66%), which in turn included in their composition five or more different EMDs each.

Source: Oral medicinal products. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Assessment of mandatory declaration excipients in pediatric off label prescriptions in Spain

Study design awaiting verification · Scientific Reports · 2025

Original publication title

Assessment of mandatory declaration excipients in pediatric off label prescriptions in Spain

Irene Lizano-Díez; Itziar Aldalur-Uranga; Antonio J. Braza; Carlos Figueiredo-Escribá; Montserrat Viñas-Bastart; Eduardo L. Mariño; Pilar Modamio

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Pediatric patients are at increased risk of exposure to potentially harmful excipients when receiving off-label medicinal products primarily formulated for adults, raising concerns about adverse events. Based on data from a previously published study, this research focuses on the most frequently prescribed off-label medicinal products in order to assess the safety of their excipients. The aim was to identify Excipients of Mandatory Declaration (EMDs) that could pose additional safety risks in individuals under the age of 18. A descriptive, and retrospective observational population-based study in individuals under 18 was developed in the Spanish primary care setting between the years 2004 to 2005 and 2017 to 2020.

The main data source was proprietary database, with nationwide coverage of prescriptions. The analysis included 4,922,984 off-label prescriptions, accounting for 16 active ingredients and 37 medicinal products (18 oral, 16 topical and three inhaled) that were scrutinized for EMD composition. Neonates and infants up to five years old accounted for nearly 50% of all off-label prescriptions among the under-18 population, exposing them to additional safety risks from potentially harmful EMDs in these formulations, which may lead to severe adverse events, causing permanent or long-term harm.

The degree of harm of EMDs was assessed overall as “severe” for nine out of 22 EMDs, mostly used for oral formulations, and “moderate” for six EMDs. No EMDs were categorized as “no harm”. Results on EMDs in oral medicinal products, for instance, highlight the urgent unmet needs in this regard, especially for young children; EMDs like sodium, sorbitol, propylene glycol and sweeteners often exceeded EMA-recommended thresholds. This study underscores the need to address risks linked to off-label use of medicinal products in children, particularly those related to EMDs.

Integrating excipient risk warnings into prescribing systems and monitoring related adverse events is strongly recommended.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-11647-x.

Authors’ abstract

Pediatric patients are at increased risk of exposure to potentially harmful excipients when receiving off-label medicinal products primarily formulated for adults, raising concerns about adverse events. Based on data from a previously published study, this research focuses on the most frequently prescribed off-label medicinal products in order to assess the safety of their excipients. The aim was to identify Excipients of Mandatory Declaration (EMDs) that could pose additional safety risks in individuals under the age of 18. A descriptive, and retrospective observational population-based study in individuals under 18 was developed in the Spanish primary care setting between the years 2004 to 2005 and 2017 to 2020.

The main data source was proprietary database, with nationwide coverage of prescriptions. The analysis included 4,922,984 off-label prescriptions, accounting for 16 active ingredients and 37 medicinal products (18 oral, 16 topical and three inhaled) that were scrutinized for EMD composition. Neonates and infants up to five years old accounted for nearly 50% of all off-label prescriptions among the under-18 population, exposing them to additional safety risks from potentially harmful EMDs in these formulations, which may lead to severe adverse events, causing permanent or long-term harm.

The degree of harm of EMDs was assessed overall as “severe” for nine out of 22 EMDs, mostly used for oral formulations, and “moderate” for six EMDs. No EMDs were categorized as “no harm”. Results on EMDs in oral medicinal products, for instance, highlight the urgent unmet needs in this regard, especially for young children; EMDs like sodium, sorbitol, propylene glycol and sweeteners often exceeded EMA-recommended thresholds. This study underscores the need to address risks linked to off-label use of medicinal products in children, particularly those related to EMDs.

Integrating excipient risk warnings into prescribing systems and monitoring related adverse events is strongly recommended.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-025-11647-x.

Publication and source details

Original title: Assessment of mandatory declaration excipients in pediatric off label prescriptions in Spain

Irene Lizano-Díez; Itziar Aldalur-Uranga; Antonio J. Braza; Carlos Figueiredo-Escribá; Montserrat Viñas-Bastart; Eduardo L. Mariño; Pilar Modamio

Scientific Reports · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:59:03.035983+00:00

DOI: 10.1038/s41598-025-11647-x · PMC12276334